Did You Take Your Medicine?

 The Analysts, based in midtown Manhattan, are made up of dozens of US-based musicians, painters, and filmmakers. The collective is helmed by LeCarner, known for exciting NYC performances, art shows, and film screenings across the region.

The Analysts are poised to introduce a new sound, comfortably left of center from New York’s avant garde techno and house scenes. They are likened to artists such as: I Hate Models, The Chemical Brothers, The London Suede, and breakbeat artists like Machine Girl. The Analysts’ sound harks back to 1960s garage tape recordings, layered in with the modern quantization of drum machines and demolished analogue synthesizers, as well as vocals to match an unsure time.

Medicine (written by LeCarner, Omar Grey, and Jim Coleman) is the lead single debuting January 13. The track brings together destructive, stimulative lead guitar work, accompanied by clean, organized bass lines and dizzying electronic drum mixing. The song’s lyrical focus leans on the sarcasm and surrealism of its generation’s voices, similar to that of early Denis Johnson works like Jesus Son and The Modern Lovers, “You don’t need no Venison, I’ll just take your Medicine.” The Analysts inject meaning into the absurd, often seemingly out of place, or off putting in principle.

The Medicine video, shot on location deep in the Colorado Rocky Mountains, shows one of The Analysts stumbling through a snow-clad forest unsure of his place or direction. The video was shot by Colorado natives Oliver Pollock and Davis Long, the video was compiled by The Analysts.

“Medicine” will soon thrust The Analysts to the sprawling, poorly lit stage of NY’s thrilling nightlife scene.

The Analysts
Jake LeCarner



  • Arts & Entertainment
  • Music

Hong Kong – Supply of medicine containing paracetamol in Hong Kong

Supply of medicine containing paracetamol in Hong Kong


     ​In response to media enquiries, a Government spokesman today (December 22) stated that the recent increase in demand for medicine for relief of pain and fever is noted, in particular certain brand of medicine containing paracetamol for use as analgesics and antipyretics. The Government stresses that the stock level of medicine containing paracetamol in the public healthcare system is sufficient and appeals to drug retail outlets such as pharmacies and supermarkets to closely monitor the sale of the relevant drugs for maintaining steady supply to those in need.

     The Government has liaised with the relevant suppliers, manufacturers, the local pharmaceutical manufacturers as well as community pharmacy associations. It was noted that there is stable supply of medicine containing paracetamol for use as analgesics and antipyretics. Even though the supply of specific brand of medicine for relief of pain and fever may be tight due to the sharp rises in demand within a short period of time, the supply of other brands of medicine for relief of pain and fever are still sufficient.

     Paracetamol could be used to relieve pain and fever. According to record, there are currently 756 pharmaceutical products containing paracetamol registered in Hong Kong. Members of the public can search the database of registered pharmaceutical products with English product names or ingredients via the search engine in the website of the Drug Office, Department of Health: www.drugoffice.gov.hk/eps/do/en/consumer/search_drug_database.html.

     According to the Pharmacy and Poisons Ordinance, Chapter 138, all pharmaceutical products must satisfy the criteria of safety, efficacy and quality and be registered with the Pharmacy and Poisons Board before they can be sold in Hong Kong. All registered pharmaceutical products should carry a Hong Kong registration number on the package in the format of “HK-XXXXX”.

     The Government spokesman urged members of the public that they should avoid buying medicine for self-medication and should consult healthcare professionals for advice before taking any medications for their conditions. The public need not stockpile any medicines including those containing paracetamol.

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Hua Medicine (the “Company”, stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early-phase insulin secretion and glucose sensitivity in patients of Type 2 diabetes (T2D).

Professor Wenying Yang of the China-Japan Friendship Hospital, and former Chairman of the Chinese Diabetes Society and currently serving as Vice President of the Asian Association for Study of Diabetes and Hua Medicine?s medical team, conducted a multivariate logistic regression analysis of the two Phase III clinical trials of dorzagliatin monotherapy (SEED), for which she participated in, and metformin add-on (DAWN), for which she served as lead principal investigator. The analysis found a significant correlation between subjects who reached blood glucose control rate after treatment and the improvement in select key measures of beta-cell secretion function, such as early-phase insulin secretion index and disposition index. The study further indicated that as a global first-in-class GKA drug, dorzagliatin can restore the deteriorated glucose-sensing function of glucokinase (GK) in T2D patients, systematically improve islet beta-cell function, improve early-phase insulin secretion and glucose sensitivity, and thereby restore the ability of T2D patients to regulate blood glucose autonomously and promote glycosylated hemoglobin levels in T2D patients (HbA1c
Conducted by Professor Jianhua Ma, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, the results of the DREAM study were also presented at ADA 2022. It is the first time that the result of diabetes remission of dorzagliatin was presented at an international academic conference, attracting widespread attention from the participants. The DREAM study is a non-drug intervention observational clinical study initiated by certain researchers participating in the SEED study. The main purpose of this study is to evaluate the remission of diabetes for 52 weeks after patients who completed the SEED study and whose blood glucose reached control targets, and stopped taking dorzagliatin as well as any other glucose-lowering medication. The results of the study showed that during the observation period when no anti-diabetes drugs were administered, the remission rate was 65.2% at 52 weeks. HbA1c, FPG and 2h-PPG levels were sustained during the 52 weeks after dorzagliatin discontinuation and beta-cell function remained stable. The study indicated that dorzagliatin has a promising treatment option for achieving remission of diabetes in newly diagnosed unmedicated patients by rapidly restoring early-phase insulin secretion and lasting improvement of beta-cell function.

Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity. The study, initiated by Professor Juliana Chan, an internationally recognized endocrinologist from the Chinese University of Hong Kong, explored the effects of dorzagliatin on patients with recent-onset T2D and glucokinase-maturity-onset diabetes of the young (GCK-MODY or MODY-2). The study results of SENSITIZE were presented to the public for the first time at the ADA Annual Scientific Sessions. The study results, using the glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent-onset T2D. As the speaker of the oral presentation and one of the researchers of the SENSITIZE study, Professor Elaine Chow from the Chinese University of Hong Kong, won the 2022 Women’s Interprofessional Network of the American Diabetes Association (WIN ADA) abstract award in the category of Clinical Diabetes, Epidemiology, and Diabetes Complications in recognition of her outstanding results and significant contributions in the SENSITIZE study and the whole field of diabetes research. The potential application of dorzagliatin in this special rare disease population of GCK-MODY, has attracted the attention of the international diabetes research field.

The WIN ADA abstract award category of Clinical Diabetes, Epidemiology and Diabetes Complications is an important part of WIN ADA awards, voted by WIN ADA Advisory Group, consisting of expert clinicians, scientists, educators, public health practitioners, and other diabetes professionals. The awards are established to recognize outstanding women who have made significant contributions to diabetes research, clinical care, public health, education, and related areas.

Dr. Li Chen, Founder, CEO and Chief Scientific Officer of Hua Medicine said, “In 2012, Hua Medicine proposed the development of GKA based on the concept of glucose homeostasis, the core of which is to treat diabetes from the root cause of T2D, addressing the issues of glucose sensitivity and insulin resistance. Concept innovation is the main focus of new drug innovation research, and Hua Medicine has spent ten years selecting a safe and effective dosing regimen and clinical study proposal suitable for most diabetic patients in China, thereby contributing to the successful development of GKA. The clinical findings presented at the ADA 2022 further demonstrate the scientific concept of dorzagliatin to ‘repair the sensor, restore homeostasis, and treat the underlying cause of diabetes’. The findings also provide a scientific basis for studies on dorzagliatin monotherapy and as a cornerstone drug in combination with other OADs for the treatment of T2D, as well as for achieving remission and regression of diabetes in patients with recent onset of T2D, and boost our confidence to further personalize diabetes treatment and to cure diabetes.”

About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive and degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By fixing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired insulin and GLP-1 secretion of patients with Type 2 diabetes and serve as a cornerstone therapy targeting the root cause of the disease. Two-Phase III registered trials for dorzagliatin monotherapy and the combination of dorzagliatin and metformin respectively have been completed in China, as well as the studies on drug mechanism synergy with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor). In an investigator-initiated study named as DREAM, a 65.2% diabetes remission rate was observed when they stopped dorzagliatin and no other antidiabetes medication was taken during the 52-week study period. The Company has obtained the “Drug Manufacturing Permit” of dorzagliatin issued by the Shanghai Medical Products Administration and has submitted its NDA to the National Medical Products Administration in order to realize the “First in Global, Start from China” mission for the benefit of diabetic patients worldwide.

About Hua Medicine
Hua Medicine is an innovative drug development company in China focused on developing novel therapies for patients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integrates global resources to explore breakthrough technologies and products and accelerate global innovation in diabetes care. Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China. This global first-in-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.

For more information
Hua Medicine
Website: www.huamedicine.com

Email: ir@huamedicine.com

Email: pr@huamedicine.com

Topic: Clinical Trial Results

The Business Take Over of Medicine is Confronted in New Novel by Beverly Hurwitz M.D.

 American Hospital Association 2021 statistics show that one out of every five U.S. hospitals is now owned by a for-profit corporation. Profiteers often select anesthesiology as a service to economize on.

In this peri-pandemic story, anesthesiologist Dr. Chessie Dolans and his physician associates suspect that falsified patient records and equipment malfunctions in their operating rooms are being deliberately caused to make it appear that their hospital’s management is incompetent. While the doctors try to block the sale of their hospital to a for-profit corporation, an FBI agent struggles to determine who’s responsible for a series of medical mishaps.

Readers of this story will come to understand that they are never more at the mercy of medical expertise than when unconscious during surgery. They’ll also become wiser about their health care choices.

Author Dr. Beverly Hurwitz has written multiple novels derived from her experience as a physician. She has also authored hiking books.

Read the first chapters – Available in kindle and paperback

Beverly Hurwitz




  • Arts & Entertainment
  • Books
  • Publishing
  • Women in Business

Hong Kong – Mainland Chinese medicine expert group of Central Authorities introduces Chinese medicine anti-epidemic plans for clinical application to Chinese medicine sector of HK (with photos/video)

Mainland Chinese medicine expert group of Central Authorities introduces Chinese medicine anti-epidemic plans for clinical application to Chinese medicine sector of HK (with photos/video)


     The expert group led by the leader of the Mainland Chinese medicine (CM) expert group of the Central Authorities, Mr Tong Xiaolin, continued its visit in Hong Kong today (April 5).


     The Secretary for Food and Health, Professor Sophia Chan, and the CM expert group participated in the afternoon a meeting on the CM anti-epidemic plans for clinical application. The CM expert group introduced the content of the plans to and exchanged views and had discussion with the CM sector representatives of Hong Kong.


     Based on the Mainland’s experience of using CM for anti-epidemic treatment, the specific epidemic situation of Hong Kong as well as the findings of its visit in Hong Kong, the expert group has prepared a set of CM anti-epidemic plans for clinical application on the basis of the existing clinical plans of Hong Kong. The plans provide for reference to the CM sector and the public guidelines on the application of CM at different levels and for different target groups, including asymptomatic patients, patients with mild symptoms, patients admitted to isolation facilities and persons in recovery.


     Attended the meeting were representatives of the CM sector including the Chairman of the Chinese Medicine Practice Subcommittee under the Chinese Medicine Development Committee (CMDC), Professor Chan Wing-kwong; the Chairman of the Chinese Medicines Industry Subcommittee under the CMDC, Mr Tommy Li; the Chairman of the Chinese Medicine Council of Hong Kong (CMCHK), Mrs Jeanie Hu; the Chairman of the Chinese Medicine Practitioners Board under the CMCHK, Dr Wong Yu-yeuk; as well as members of the relevant committees.  The meeting was moderated by Professor Feng Jiu, the former Chairman of the Chinese Medicine Practice Subcommittee under the CMDC.  Representatives from the Food and Health Bureau, Department of Health and Hospital Authority also attended.


     “On behalf of the Hong Kong Special Administrative Region (HKSAR) Government, I would like to express my heartfelt gratitude to Mr Tong Xiaolin for leading the CM expert group to visit Hong Kong and provide guidance on the CM epidemic prevention and anti-epidemic work in Hong Kong.  Within just one week after arriving in Hong Kong, the expert group has already paid site visits to different facilities, and met with various stakeholders in the CM sector, with a view to gaining an in-depth understanding of the actual situation of the use of CM at different levels of epidemic prevention and control in Hong Kong,” said Professor Chan.


     “The meeting today is an excellent opportunity for the CM expert group to share the content of the plans with the CM sector of Hong Kong.  The CMDC and CMCHK are both important stakeholders in promoting the development of CM in Hong Kong. I call on the attendees to further promote the plans drawn up by the CM expert group to members of their affiliated organisations, thereby serving as a reference for more members of the public and CM practitioners. The HKSAR Government will also step up its publicity to promote to the public relevant information regarding the use of CM in epidemic prevention and control,” supplemented Professor Chan.


     “The CM expert group has also put forward the ‘three easy’ principles – ‘easy to understand’, ‘easy to do’ and ‘easy to get’. The HKSAR Government will follow up and implement the relevant recommendations, with a view to giving full play to the advantages and effectiveness of CM in fighting the epidemic, thereby further promoting the development of CM in Hong Kong,” Professor Chan continued.


     Led by Mr Tong, the Mainland CM expert group arrived in Hong Kong on March 29 to conduct visits.